Shares of Albireo Pharma, Inc. (NASDAQ:ALBO) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $75.00.

ALBO has been the subject of a number of analyst reports. Zacks Investment Research raised Albireo Pharma from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Wednesday, October 25th. Roth Capital initiated coverage on Albireo Pharma in a report on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price target for the company. Cowen and Company reissued a “buy” rating on shares of Albireo Pharma in a report on Friday. Wedbush reissued an “outperform” rating and issued a $58.00 price target on shares of Albireo Pharma in a report on Monday, September 11th. Finally, ValuEngine cut Albireo Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/30/biodel-inc-albo-receives-average-rating-of-buy-from-brokerages.html.

Albireo Pharma (ALBO) traded up $0.42 during midday trading on Monday, hitting $25.99. The stock had a trading volume of 15,800 shares, compared to its average volume of 23,793. Albireo Pharma has a 12 month low of $15.31 and a 12 month high of $37.69.

Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.02). equities research analysts anticipate that Albireo Pharma will post -3.6 EPS for the current year.

An institutional investor recently raised its position in Albireo Pharma stock. Renaissance Technologies LLC boosted its holdings in Albireo Pharma, Inc. (NASDAQ:ALBO) by 0.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 149,632 shares of the biopharmaceutical company’s stock after purchasing an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Albireo Pharma were worth $3,591,000 as of its most recent filing with the Securities and Exchange Commission. 27.29% of the stock is owned by institutional investors.

Albireo Pharma Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.